Recently, a new study presented at the Annual Meeting of the Radiological Society of North America (RSNA) showed that in brains of patients affected with Alzheimer’s disease, changes in brain connections can be visualized by Magnetic resonance imaging (MRI). Alzheimer’s disease is currently estimated to affect approximately 5 million…
A drug that is usually used for treatment of psoriasis has been found to stimulate the activity of the enzyme ADAM10 in the brain of Alzheimer’s patients (AD), providing encouraging results for treating the disease. The study, which was recently published in the journal Neurology, entitled “…
A new study published this week in the Journal of Neuroscience suggests a potential therapy for a type of neurotransmitter receptor for Frontotemporal Dementia. The study entitled ”Tau-Mediated NMDA Receptor Impairment Underlies Dysfunction of a Selectively Vulnerable Network in a Mouse Model of Frontotemporal Dementia,” was…
Eli Lilly and Company and AstraZeneca announced the start of recruitment of patients for the Phase II/III AMARANTH clinical trial of an inhibitor of beta secretes cleaving enzyme (BACE), currently under development as a promising therapy for Alzheimer’s disease. Alzheimer’s disease is characterized by two important pathological features —…
A study performed at Ghent University in Belgium suggests an association between language skills and the onset of Alzheimer disease symptoms. In the study, a team of both psychologists and neurologists analyzed two different groups of patients with a probable risk to develop Alzheimer’s disease and separated according to their…
According to the Institute for Scientific Information on Coffee (ISIC), a nonprofit organization that specializes in biomedical research and information dissemination on the health benefits of coffee, people who drink about 3 to 5 cups of coffee per day may be less likely to develop Alzheimer’s Disease.
Researchers from the School of Medicine at Washington University in St. Louis (WUSTL) blocked a sleep-regulating protein, orexin, in mice with a form of Alzheimer’s disease, making them sleep longer and blocking brain symptoms of Alzheimer’s disease. The research appeared Nov. 24 in The Journal of Experimental Medicine.
Biogen Idec, the company behind several of today’s most widely sold multiple sclerosis drugs, has been developing a novel treatment for Alzheimer’s disease, called BIIB037, which has shown great potential in blocking beta amyloid — one of the hallmarks of this common form of dementia…
A new study entitled “Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease” reports a correlation between α-synuclein and amyloid-β in the brain of patients affected by neurodegenerative diseases, such as Parkinson’s disease. The study was published in the…
A large study entitled “Genome-wide studies of verbal declarative memory in non-demented older people: the CHARGE consortium” was recently published in the journal Biological Psychiatry and sought to identify the genetics of memory function in older individuals. One of the most essential aspects of human cognition is the…
Get regular updates to your inbox.